ESTA Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -20.72% compared to Establishment Labs Holdings, Inc.'s net margin of --. Establishment Labs Holdings, Inc.'s return on equity of -253.79% beat CEL-SCI Corp.'s return on equity of -266.61%.

Establishment Labs Holdings, Inc. has a consensus price target of $74.22, signalling upside risk potential of 4.94%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Establishment Labs Holdings, Inc., analysts believe CEL-SCI Corp. is more attractive than Establishment Labs Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $53.8M, which are larger than CEL-SCI Corp. quarterly revenues of --. Establishment Labs Holdings, Inc.'s net income of -$11.1M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 10.83x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -20.72% compared to Establishment Labs Holdings, Inc.'s net margin of -953.4%. Establishment Labs Holdings, Inc.'s return on equity of -253.79% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Establishment Labs Holdings, Inc. has a consensus price target of $74.22, signalling upside risk potential of 4.94%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Establishment Labs Holdings, Inc., analysts believe IGC Pharma, Inc. is more attractive than Establishment Labs Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $53.8M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Establishment Labs Holdings, Inc.'s net income of -$11.1M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 10.83x versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Medpace Holdings, Inc. has a net margin of -20.72% compared to Establishment Labs Holdings, Inc.'s net margin of 16.84%. Establishment Labs Holdings, Inc.'s return on equity of -253.79% beat Medpace Holdings, Inc.'s return on equity of 78.26%.

Establishment Labs Holdings, Inc. has a consensus price target of $74.22, signalling upside risk potential of 4.94%. On the other hand Medpace Holdings, Inc. has an analysts' consensus of $538.58 which suggests that it could fall by -1.74%. Given that Establishment Labs Holdings, Inc. has higher upside potential than Medpace Holdings, Inc., analysts believe Establishment Labs Holdings, Inc. is more attractive than Medpace Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison Medpace Holdings, Inc. has a beta of 1.427, suggesting its more volatile than the S&P 500 by 42.743%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medpace Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. Medpace Holdings, Inc. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $53.8M, which are smaller than Medpace Holdings, Inc. quarterly revenues of $659.9M. Establishment Labs Holdings, Inc.'s net income of -$11.1M is lower than Medpace Holdings, Inc.'s net income of $111.1M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while Medpace Holdings, Inc.'s PE ratio is 38.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 10.83x versus 7.03x for Medpace Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of -20.72% compared to Establishment Labs Holdings, Inc.'s net margin of -10.08%. Establishment Labs Holdings, Inc.'s return on equity of -253.79% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

Establishment Labs Holdings, Inc. has a consensus price target of $74.22, signalling upside risk potential of 4.94%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 114.52%. Given that The Oncology Institute, Inc. has higher upside potential than Establishment Labs Holdings, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Establishment Labs Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.817%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $53.8M, which are smaller than The Oncology Institute, Inc. quarterly revenues of $136.6M. Establishment Labs Holdings, Inc.'s net income of -$11.1M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 10.83x versus 0.56x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.